Baudax Bio, Inc.
BXRX · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $1,269 | $1,080 | $493 | $0 |
| % Growth | 17.5% | 119.1% | – | – |
| Cost of Goods Sold | $7,009 | $2,445 | $1,732 | $0 |
| Gross Profit | -$5,740 | -$1,365 | -$1,239 | $0 |
| % Margin | -452.3% | -126.4% | -251.3% | – |
| R&D Expenses | $5,884 | $3,125 | $9,087 | $20,061 |
| G&A Expenses | $14,713 | $0 | $0 | $27,012 |
| SG&A Expenses | $24,119 | $45,310 | $43,335 | $27,012 |
| Sales & Mktg Exp. | $9,406 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $2,576 | $2,146 | -$38 |
| Operating Expenses | $30,003 | $51,011 | $54,568 | $47,073 |
| Operating Income | -$35,743 | -$19,006 | -$74,786 | -$32,519 |
| % Margin | -2,816.6% | -1,759.8% | -15,169.6% | – |
| Other Income/Exp. Net | -$23,052 | $32,607 | -$1,314 | $7,316 |
| Pre-Tax Income | -$58,795 | -$19,769 | -$76,100 | -$32,557 |
| Tax Expense | $0 | $0 | $0 | -$14,554 |
| Net Income | -$58,795 | -$19,769 | -$76,100 | -$18,003 |
| % Margin | -4,633.2% | -1,830.5% | -15,436.1% | – |
| EPS | -177.3 | -361.16 | -5,715.36 | -2,695.87 |
| % Growth | 50.9% | 93.7% | -112% | – |
| EPS Diluted | -177.3 | -361.16 | -5,715.36 | -2,695.87 |
| Weighted Avg Shares Out | 332 | 55 | 13 | 7 |
| Weighted Avg Shares Out Dil | 332 | 55 | 13 | 7 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1,359 | $0 |
| Interest Expense | $21,070 | $2,303 | $1,359 | $0 |
| Depreciation & Amortization | $2,162 | -$29,254 | $21,578 | -$28,628 |
| EBITDA | -$35,578 | -$48,260 | -$74,786 | -$39,393 |
| % Margin | -2,803.6% | -4,468.5% | -15,169.6% | – |